Case Report

Fatal Pediatric COVID-19 Case With Seizures and Fulminant Cerebral Edema

Siddharth Ninan, MBBS, MD, Peyton Thompson, MD, MSCR, Timothy Gershon, MD, PhD, Natalie Ford, MD, William Mills, MD, MPH, Valerie Jewells, DO, Leigh Thorne, MD, Katherine Saunders, DO, Thomas Bouldin, MD, Jason R. Smedberg, PhD, Melissa B. Miller, PhD, Eveline Wu, MD, Alyssa Tilly, MD, Jeremy Sites, MD, Daniel Lercher, MD, Katherine Clement, MD, Tracie Walker, MD, Paul Shea, MD, Benny Joyner, MD, MPH, and Rebecca Smith, MD

Abstract
The novel coronavirus, SARS-CoV-2, can present with a wide range of neurological manifestations, in both adult and pediatric populations. We describe here the case of a previously healthy 8-year-old girl who presented with seizures, encephalopathy, and rapidly progressive, diffuse, and ultimately fatal cerebral edema in the setting of acute COVID-19 infection. CSF analysis, microbiological testing, and neuropathology yielded no evidence of infection or acute inflammation within the central nervous system. Acute fulminant cerebral edema (AFCE) is an often fatal pediatric clinical entity consisting of fever, encephalopathy, and new-onset seizures followed by rapid, diffuse, and medically-refractory cerebral edema. AFCE occurs as a rare complication of a variety of common pediatric infections and a CNS pathogen is identified in only a minority of cases, suggesting a para-infectious mechanism of edema. This report suggests that COVID-19 infection can precipitate AFCE, and highlights the need for high suspicion and early recognition thereof.

Keywords
COVID-19, pediatric, seizures, cerebral edema

Received December 31, 2020. Received revised February 12, 2021. Accepted for publication May 16, 2021.

COVID-19, caused by the novel SARS-CoV-2 virus, emerged in December 2019 causing widespread morbidity and mortality. Coronaviruses have associated neurological manifestations, as noted during the SARS (2002) and MERS (2012) epidemics. Multiple neurological manifestations of COVID-19 have been described in children, including encephalitis/encephalopathy, seizure-like activity, and peripheral weakness.

1 Department of Neurology, University of North Carolina at Chapel Hill, NC, USA
2 Department of Pediatrics, Division of Infectious Diseases, University of North Carolina at Chapel Hill, NC, USA
3 Department of Pediatrics, University of North Carolina at Chapel Hill, NC, USA
4 Department of Pediatrics, Division of Emergency Medicine, University of North Carolina at Chapel Hill, NC, USA
5 Department of Radiology, University of North Carolina at Chapel Hill, NC, USA
6 Department of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, NC, USA
7 Clinical Microbiology Laboratory, McLendon Clinical Laboratories, UNC Medical Center, Chapel Hill, NC
8 Department of Pediatrics, Division of Allergy, Immunology and Rheumatology, University of North Carolina at Chapel Hill, NC, USA
9 Departments of Medicine and Pediatrics, Palliative Care Program, University of North Carolina at Chapel Hill, NC, USA
10 Department of Pediatrics, Division of Critical Care, University of North Carolina at Chapel Hill, NC, USA

Corresponding Author:
Siddharth Ninan, MBBS, MD, Department of Neurology, University of North Carolina at Chapel Hill, 101 Manning Drive, NC, 27514 USA.
Email: siddharth.ninan@unch.unc.edu
Acute fulminant cerebral edema (AFCE) is a poorly understood clinical entity characterized by fever, encephalopathy and often new seizures followed by rapid progression to diffuse cerebral edema, with potentially fatal outcomes. Postmortem examination of the brain in fatal cases of AFCE confirms diffuse brain edema but does not reveal an underlying cause, such as meningitis, encephalitis, brain infarcts, hypoxic-ischemic encephalopathy, or toxic/metabolic encephalopathy. We report a child with acute seizures and acute fulminant cerebral edema in the context of COVID-19 infection.

Case History

A previously healthy 8-year-old Latina female presented to our emergency department (ED) with 1 day of fever (T_max 100.4°F), lethargy, myalgias, anorexia, and new-onset seizure-like activity. She was diagnosed with group A streptococcal (GAS) pharyngitis and COVID-19 at an urgent care clinic, just prior to presenting to the ED. En route to retrieve antibiotics for GAS, she developed emesis, altered consciousness, and had a 2-minute, self-resolving period of seizure-like activity, described as generalized convulsions and drooling. The patient was previously healthy without prior hospitalizations, up-to-date on immunizations, and without known head trauma, drug allergies, inadvertent ingestions, or daily medications.

Her vital signs in the ED were: rectal temperature 38.9°C, heart rate 88, respiratory rate 33, blood pressure 92/69, SpO2 91% on room air. She was awake but drowsy and in no acute distress. Neurological examination revealed mild confusion, mildly reduced verbal output with appropriate responses to simple questions, inconsistent ability to follow commands, no focal motor deficits and no meningeal signs. Skin examination revealed a pink, fine macular rash wrapping around her trunk and upper extremities, sparing her palms/soles. She had posterior pharyngeal erythema without tonsillar hypertrophy or exudate. The remainder of the examination was unremarkable.

The patient remained stable for a 2-hour period until resumption of seizure activity, consisting of 1 minute of generalized convulsions followed by decorticate posturing of the limbs, trismus, right head version, and alternating right and left eye deviation. Pupils remained equal, round and reactive to light throughout. She had an episode of emesis during the seizure with suspected aspiration; her SpO2 dropped as low as 86% but quickly corrected to > 92% on 4 L O2. Her seizures were unresponsive to 2 doses of intravenous lorazepam (0.1 mg/kg), but terminated with a loading bolus of levetiracetam (60 mg/kg) after 25 minutes.

Initial laboratory evaluation revealed a normocytic anemia, slightly elevated AST, and slightly elevated C-reactive protein (Table 1). A nasopharyngeal swab for SARS-CoV-2 RT-PCR returned positive. After a blood culture was collected (which ultimately revealed no growth), broad-spectrum antimicrobials (vancomycin, ceftriaxone, and acyclovir) were initiated for possible meningitis. Chest X-ray showed prominent right peripheral and bibasilar lung markings. A non-contrast head CT following her seizure episode in the ED showed sulcal loss suggesting global edema, without evidence of herniation. Given her failure to return to her baseline mental status she was admitted to the Pediatric Intensive Care Unit (PICU) for continuous video EEG (cVEEG) and closer monitoring.

On arrival to the PICU the patient was minimally responsive, with intermittent decerebrate posturing, rhythmic upper extremity flexion, and twitching of all 4 extremities; pupils remained equal, round, and reactive to light bilaterally. In response to her intermittent rhythmic movements, she received 3 additional doses of lorazepam 0.04 mg/kg (paced 10-15 minutes apart) while awaiting a fosphenytoin loading dose. cVEEG - initiated within 1 hour of PICU arrival - revealed a symmetric but attenuated background, without epileptiform activity. She experienced short episodes of hypertension and tachycardia but was never bradycardic, nor persistently hypertensive. Her respiratory rate declined approximately 1 h after arrival to the PICU, requiring emergent intubation, at which time she had no cough or gag reflex. Post-intubation, she developed fluid-refractory hypotension necessitating inotropic and vasopressor support. She had no response to painful stimuli on central line placement and her pupils were fixed and dilated (1.5 hours into her PICU stay). She then received hypertonic saline and mannitol given concern for elevated intracranial pressure (ICP). After stabilization, she was taken emergently for a brain MRI, which revealed diffuse cerebral edema, slit-like lateral ventricles, crowding of the basal cisterns and early downward herniation with kinking at the spinothalamic junction. There was no restricted diffusion. MRA demonstrated absent or minimal flow beyond the proximal segments of the major cerebral arteries, consistent with elevated ICP limiting cerebral perfusion. Also noted were mild, diffuse T2/FLAIR hyperintensities throughout both the deep and superficial gray matter suggesting a global, gray matter-focused process (Figure 1). She received IV dexamethasone in attempts to reduce cerebral edema. Post-MRI, she developed pulseless ventricular tachycardia requiring 2 minutes of CPR before return of spontaneous circulation. Regarding immunomodulatory therapy, she received intravenous immunoglobulin (2 g/kg), anakinra, and hydrocortisone; despite approval for remdesivir and COVID-19 convalescent plasma, these were ultimately withheld due to poor prognosis. Brain death examinations at 24 and 48 hours post-cardiac arrest were consistent with brain death. Repeat MRI between brain death examinations showed further limited cerebral perfusion and progression of uncal/onsiilar herniation. She was pronounced dead at the time of the second brain death examination.

Lumbar puncture performed immediately post-mortem yielded clear CSF with normal glucose (64 mg/dL), highly elevated protein (>1,500 mg/dL), 1 RBC, and 4 nucleated cells (50% neutrophils, 11% lymphocytes), indicating no encephalitis or meningitis. CSF culture was negative for bacteria and fungi. Extensive infectious disease testing was unrevealing for a cause of death (Table 1). Postmortem brain examination demonstrated global brain edema with mass effect leading to transtentorial herniation, rare red neurons in the cerebrum and
Table 1. Initial Laboratory and Microbiological Findings.

| Parameter                      | Patient’s value | Units       | Reference value |
|--------------------------------|-----------------|-------------|-----------------|
| Complete Blood Count           |                 |             |                 |
| White blood cell count         | 6.9             | $10^9$/L    | 4.5-13.0        |
| Hemoglobin                     | 10.6            | g/dL        | 13.0-16.0       |
| MCV                            | 83.4            | fL          | 78.0-98.0       |
| Platelet count                 | 183             | $10^9$/L    | 150-440         |
| Complete metabolic panel       |                 |             |                 |
| Sodium                         | 143             | mmol/L      | 135-145         |
| Potassium                      | 4.3             | mmol/L      | 3.4-4.7         |
| Chloride                       | 105             | mmol/L      | 98-107          |
| CO2                            | 22.0            | mmol/L      | 22.0-30.0       |
| BUN                            | 12              | mg/dL       | 5-17            |
| Creatinine                     | 0.39            | mg/dL       | 0.30-0.90       |
| Anion gap                      | 16              | mmol/L      | 7-15            |
| Glucose                        | 128             | mg/dL       | 70-179          |
| Calcium                        | 9.0             | mg/dL       | 8.8-10.8        |
| Magnesium                      | 2.0             | mg/dL       | 1.6-2.2         |
| Phosphorus                      | 3.9             | mg/dL       | 4.0-5.7         |
| Albumin                        | 4.1             | g/dL        | 3.5-5.0         |
| Total Protein                  | 7.9             | g/dL        | 6.5-8.3         |
| Total Bilirubin                | 0.2             | mg/dL       | 0.0-1.2         |
| AST                            | 53              | U/L         | 10-40           |
| ALT                            | 37              | U/L         | <50             |
| Alkaline Phosphatase           | 132             | U/L         | 130-560         |
| Cardiac Enzymes                |                 |             |                 |
| Troponin I                     | <0.034          | ng/mL       | <0.034          |
| Pro-BNP                        | 547.0           | pg/mL       | 0.0-178.0       |
| ESR                            | 19.0            | mm/h        | 0-20            |
| CRP                            | 19.1            | mg/dL       | <10.0           |
| LDH                            | 742             | U/L         | 380-770         |
| Coagulation Panel              |                 |             |                 |
| PT                             | 14.4            | sec         | 10.2-13.1       |
| INR                            | 1.25            | N/A         | N/A             |
| APTT                           | 36.5            | sec         | 25.9-39.5       |
| D-Dimer                        | 3,493           | DDU         | <230            |
| Fibrinogen                     | 316             | mg/dL       | 177-386         |
| Infectious Disease Test Results|                 |             |                 |
| SARS-CoV-2 PCR (nasopharyngeal)| Positive        | N/A         | Negative        |
| SARS-CoV-2 PCR (CSF)           | Negative        | N/A         | Negative        |
| Blood culture                  | No growth       | N/A         | No growth       |
| CSF culture                    | No growth       | N/A         | No growth       |
| 4th generation HIV Ag/Ab       | Negative        | N/A         | Negative        |
| CMV PCR (serum and CSF)        | Undetectable    | N/A         | Undetectable    |
| EBV PCR (serum and CSF)        | Undetectable    | N/A         | Undetectable    |
| HHV-6 PCR (serum and CSF)      | Undetectable    | N/A         | Undetectable    |
| HSV 1/2 PCR (serum and CSF)    | Undetectable    | N/A         | Undetectable    |
| VZV PCR (serum and CSF)        | Undetectable    | N/A         | Undetectable    |
| Enterovirus PCR (serum and CSF)| Undetectable    | N/A         | Undetectable    |
| Arbovirus panel (CSF)          | Negative        | N/A         | Negative        |
| Parvovirus B-19 PCR (serum)    | Undetectable    | N/A         | Undetectable    |
| Bartonella antibody panel (serum)| Negative      | N/A         | Negative        |
| LCMV PCR/antibody (serum and CSF)| Negative    | N/A         | Negative        |
| Naegleria PCR (CSF)            | Undetectable    | N/A         | Undetectable    |
| Balamuthia PCR (CSF)           | Undetectable    | N/A         | Undetectable    |
| Acanthamoeba PCR (CSF)         | Undetectable    | N/A         | Undetectable    |
| Baylisascaris procyonis Ab (serum)| Negative      | N/A         | Negative        |
| Postmortem Microbiological Results |                 |             |                 |
| Aerobic culture, left lung     | Candida parapsilosis³, Lactobacillus | N/A | No growth |
| Aerobic culture, right lung    | No growth       | N/A         | No growth       |
| Aerobic culture, brain tissue  | <1+ Candida parapsilosis² | N/A | No growth |
| Aerobic/anaerobic culture, spleen | No growth   | N/A         | No growth       |
| AFB smear/culture, left lung   | No growth       | N/A         | No growth       |

(continued)
Table 1. (continued)

| Parameter                                      | Patient’s value | Units | Reference value |
|------------------------------------------------|-----------------|-------|-----------------|
| AFB smear/culture, right lung                  | No growth       | N/A   | No growth       |
| AFB smear/culture, brain tissue                | No growth       | N/A   | No growth       |
| Fungal culture, left lung                      | 4+ Candida parapsilosis¹ | N/A   | No growth       |
| Fungal culture, right lung                     | No growth       | N/A   | No growth       |
| Fungal culture, brain tissue                   | No growth       | N/A   | No growth       |
| Respiratory pathogen panel, left lung          | Negative        | N/A   | Negative        |
| Respiratory pathogen panel, right lung         | Negative        | N/A   | Negative        |
| SARS-CoV-2 PCR (blood)                         | Negative        | N/A   | Negative        |
| SARS-CoV-2 PCR (brain tissue)                  | Negative        | N/A   | Negative        |
| SARS-CoV-2 PCR (left lung)                     | Negative        | N/A   | Negative        |
| SARS-CoV-2 PCR (right lung)                    | Negative        | N/A   | Negative        |

* Initial laboratory findings obtained while patient was in the emergency department.

¹This fungal growth was likely related to the patient’s known aspiration event.

²Growth from aerobic culture of brain tissue was believed to be contamination from lung tissue at time of autopsy; growth in only 1 of 2 aerobic cultures from brain tissue.

Figure 1. Brain imaging (MRI/MRA/MRV). Day #1 brain MRI (A) sagittal T1 image demonstrates downward herniation with decreased size of the suprasellar cistern, posterior fossa crowding causing brainstem compression against the clivus and developing tonsillar herniation. (B) MRV demonstrates patent jugular veins and transverse sinuses without thrombosis. The sagittal sinus and deep venous system are not visible. (C) T2 axial images reveal diffuse cortical swelling mild, global gray matter hyperintensity, and slit-like ventricles suggesting brain edema. (D) coronal MRA image demonstrates near complete or complete loss ACA, MCA, PCA and basilar flow. (E) susceptibility-weighted imaging shows exaggerated cortical veins consistent with engorgement vs thrombosis. The subsequent MRI sagittal T1 (F), day #2 demonstrates tonsillar herniation down to the level of C2. MRIs on day #1 and 2 revealed bilateral parotid cysts (G), suggesting parotitis, which has been reported in cases of COVID-19 infection.²¹,²²
cerebellum consistent with acute ischemic neuronal necrosis, and a very small number of chronic inflammatory cells in the leptomeninges and around a few intraparenchymal blood vessels. There was no evidence of encephalitis, large- or small-vessel vasculitis or thrombosis, or perivascular demyelination. Findings of chronic lymphocytic thyroiditis on autopsy and parotid cysts on brain MRI raised concerns for a possible underlying autoimmune condition. Thyroid testing performed on salvaged serum revealed an elevated TSH (8.924 uIU/mL; reference range 0.50-4.50) with normal free T4 (1.62 ng/dL; reference range 0.8-2.0). Thyroid antibodies were unable to be sent. Parents reported no known underlying medical/autoimmune conditions and no family history of autoimmune disease. Postmortem lung cultures grew Candida parapsilosis, likely related to the aspiration event. The remainder of the postmortem cultures were unremarkable (Table 1). CSF, blood, brain tissue, and bilateral lungs were negative for SARS-CoV-2 RNA by RT-PCR.

Discussion

The pathogenetic mechanisms of the diverse neurological manifestations of COVID-19 are uncertain, though the ability of SARS-CoV-2 to invade cells using the ACE2 receptor has been confirmed. AFCE is characterized clinically by rapidly increasing ICP with neurological deterioration (GCS < 8, signs and symptoms of brainstem dysfunction) while imaging demonstrates cerebral edema and herniation. This is a rarely described but often fatal acute encephalopathic process, of which the majority of cases are associated with preceding seizures. In this case, the fulminant cerebral edema seems neither a direct viral effect, given the absence of SARS-CoV-2 RNA in the CSF and brain parenchyma, nor secondary to encephalitis, evidenced by the lack of inflammation on CSF indices and on neuropathological examination. Similarly, both cohorts of AFCE described to date note a variety of associated common pediatric infections, with a CNS pathogen identified in only a minority of cases. The heterogeneity of infections associated with AFCE suggests a gene-environment interaction in which common infections precipitate this phenotype in susceptible individuals.

Considering other potential etiologies of the patient’s diffuse cerebral edema, global hypoxic-ischemic encephalopathy seems unlikely given her continuous SpO2 monitoring and telemetry without prolonged desaturations or cardiac arrest prior to her precipitous neurological decline. Status epilepticus is also an unlikely etiology, as seizure-related cerebral edema is reported to develop over the course of 1 - 5 days rather than the 12 hours seen in this case. Arterial and venous thromboses were excluded at autopsy. Despite confirmed GAS pharyngitis, the lack of bacterial meningitis, bacteremia, or acute inflammation at postmortem examination suggests that bacterial pathogens did not directly cause her decline. The very scant chronic perivascular and leptomeningeal inflammation seen on autopsy is nonspecific, does not suggest a para-infectious cerebritis or vasculitis, and likely represents an inflammatory reaction to the brain ischemia associated with her prolonged increased intracranial pressure. Her markedly elevated CSF protein is nonspecific and confounded by the timing of lumbar puncture relative to cerebral anoxia. The chronic lymphocytic thyroiditis on autopsy and parotid cysts on MRI raise the possibility of an unrecognized autoimmune disease contributing to the severity of her case, however we were limited in the volume of scavenged blood remaining for additional etiologic testing. The pathologic systemic immune response and cytokine storm in SARS-CoV-2 infection is an increasingly recognized mediator of severe COVID-19 infection, and the same deranged immune response has been associated with diffuse cerebral edema, both within the context of acute viral infection and without. Finally, it has been hypothesized that perturbations of energy metabolism through mitochondrial fatty acid oxidation may lead to adenosine triphosphate utilization failure and cytotoxic brain edema.

While much remains uncertain about the pathophysiological mechanisms of COVID-19 and AFCE, this case shows that SARS-CoV-2 childhood infection may present with AFCE in previously healthy children. This presentation is distinct from a previously reported case of fatal cerebral edema in child with SARS-CoV-2, in which elevated intracranial pressure developed in the context of SARS-CoV-2-associated multisystem inflammatory syndrome. In that case, neuropathology showed diffuse inflammation, while we did not find evidence of significant brain pathology on postmortem examination. Additionally, encephalopathy was part of our patient’s initial presentation. The previously reported case shows that fatal cerebral edema may complicate pediatric multisystem inflammatory syndrome, while our case indicates that COVID-19 infection may directly trigger AFCE. The rapid and devastating clinical course in both of these cases highlights the need for early recognition of a cerebral edema and AFCE as potential complications of COVID-19 in pediatric patients.

Abbreviations

MCV, mean corpuscular volume; CO2, bicarbonate; BUN, blood urea nitrogen; AST, aspartate aminotransferase; ALT, alanine aminotransferase; BNP, brain natriuretic peptide; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; LDH, lactate dehydrogenase; PT, prothrombin time; INR, international normalized ratio; APTT, activated partial thromboplastin time. SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; PCR, polymerase chain reaction; CSF, cerebrospinal fluid; HIV, human immunodeficiency virus; Ag/Antigen/Antibody; CMV, cytomegalovirus; EBV, Ebstein-Barr virus; HHV-6, human herpesvirus 6; HSV, herpes simplex virus; VZV, varicella zoster virus; LCMV, lymphocytic choriomeningitis virus; AFb, acid-fast bacilli.

Acknowledgements

We would like to acknowledge the patient’s family and friends in the tragic loss of their beloved little girl. We also recognize all of the medical staff who are not named here who helped to take care of her during her hospital stay.
Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding
The author(s) received no financial support for the research, authorship, and/or publication of this article.

ORCID iD
Siddharth Ninan, MBBS, MD https://orcid.org/0000-0001-6713-8790
Peyton Thompson, MD, MSCR https://orcid.org/0000-0002-9679-9763
Thomas Bouldin, MD https://orcid.org/0000-0001-8963-9836

References
1. Wu Y, Xu X, Chen Z, et al. Nervous system involvement after infection with COVID-19 and other coronaviruses. Brain Behav Immun. 2020;87:18-22.
2. McAbee GN, Bros gol Y, Pav lakis S, A gha R, G affoor M. En cephalitis associated with COVID-19 infection in an 11-year-old child. Pediatr Neurol. 2020;109:94.
3. Abdel-Mannan O, Eyre M, Löbel U, et al. Neurologic and radiographic findings associated with COVID-19 infection in children. JAMA Neurol. 2020;77(11):1440-1445.
4. Dugue R, Cay-Martínez KC, Thakur KT, et al. Neurologic manifestations in an infant with COVID-19. Neurology. 2020;94(24):1100-1102.
5. Chen TH. Neurological involvement associated with COVID-19 infection in children. J Neurol Sci. 2020;418.
6. Asadi-Pooya AA, Simani L. Central nervous system manifestations of COVID-19: a systematic review. J Neurol Sci. 2020;413:116832-116832.
7. Bhatta S, Sayed A, Ranabhat B, Bhatta RK, Acharya Y. New-onset seizure as the only presentation in a child with COVID-19. Curr Neurol Neurosci Rep. 2020;12(6):e8820-e8820.
8. Lan SY, Lin JJ, Hsia SH, et al. Analysis of fulminant cerebral edema in acute pediatric encephalitis. Pediatr Neonatol. 2016;57(5):402-407.
9. Krishnan P, Glenn OA, Samuel MC, et al. Acute fulminant cerebral edema: a newly recognized phenotype in children with suspected encephalitis. J Pediatr Infect Dis Soc. 2020;10(3):289-294.
10. Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270-273.
11. Kumar G, Kalita J, Misra U. Raised intracranial pressure in acute viral encephalitis. Clin Neurol Neurosurg. 2009;111(5):399-406.
12. Myers KA, McMahon JM, Mandelstam SA, et al. Fatal cerebral edema with status epilepticus in children with dravet syndrome: report of 5 cases. Pediatrics. 2017;139(4):e20161933.
13. Xu X, Han M, Li T, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci USA. 2020;117(20):10970-10975.
14. Luo P, Liu Y, Qiu L, Liu X, Liu D, Li J. Tocilizumab treatment in COVID-19: a single center experience. J Med Virol. 2020;92(7):814-818.
15. Zhang C, Wu Z, Li JW, Zhao H, Wang GQ. Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality. Int J Antimicrob Agents. 2020;55(5):105954.
16. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033-1034.
17. Kakimoto Y, Seto Y, Ochiai E, Satoh F, Osawa M. Cytokine elevation in sudden death with respiratory syncytial virus: a case report of 2 children. Pediatrics. 2016;138(6):e20161293.
18. Radmanesh F, Rodriguez-Pla A, Pincus MD, Burns JD. Severe cerebral involvement in adult-onset hemophagocytic lymphohistiocytosis. J Clin Neurosci. 2020;76:236-237.
19. Chen Y, Mizuguchi H, Yao D, et al. Thermolabile phenotype of carnitine palmitoyltransferase II variations as a predisposing factor for influenza-associated encephalopathy. FEBS Lett. 2005;579(10):2040-2044.
20. Kim MG, Stein AA, Overby P, et al. Fatal cerebral edema in a child with COVID-19. Pediatr Neurol. 2020.[Pre-proof].
21. Lechien J, Chetrit A, Chêkkoury-Idrissi Y, et al. Parotitis-like symptoms associated with COVID-19, France, March–April 2020. Emerg Infect Dis J. 2020;26(9):2270.
22. Fisher J, Monette DL, Patel KR, Kelley BP, Kennedy M. COVID-19 associated parotitis: a case report. Am J Emerg Med. 2020;39:254.e1-254.e3.